Atypical Glycine Encephalopathy

Introduction

Atypical glycine encephalopathy, often referred to as partial or late-onset nonketotic hyperglycinemia (NKH), is a rare genetic metabolic disorder characterized by an impaired ability to break down the amino acid glycine. While the classical form of NKH typically presents with severe, life-threatening symptoms in newborns, atypical glycine encephalopathy encompasses a spectrum of presentations, often with a later onset and a less severe clinical course. This variability makes diagnosis challenging and highlights the importance of understanding its underlying mechanisms.

Biological Basis

The core biological defect in atypical glycine encephalopathy involves the glycine cleavage system (GCS), a multi-enzyme complex critical for the catabolism of glycine. This system is primarily active in the brain and liver and consists of four protein components: P-protein (GLDC), H-protein (GCSH), T-protein (GCST), and L-protein (DLD). Mutations in the genes encoding these proteins, particularly GLDC(glycine decarboxylase) orAMT(aminomethyltransferase, which encodes the T-protein), lead to reduced GCS activity. This deficiency results in an accumulation of glycine, especially in the brain and cerebrospinal fluid. Elevated glycine levels disrupt normal neurotransmission, as glycine acts as both an inhibitory neurotransmitter at certain receptors and an excitatory neurotransmitter atNMDA receptors, leading to neurological dysfunction. The “atypical” nature suggests some residual GCS activity, which accounts for the milder or later-onset phenotype compared to severe classical NKH.

Clinical Relevance

The clinical manifestations of atypical glycine encephalopathy are diverse, ranging from mild developmental delays, learning difficulties, and behavioral issues to more pronounced intellectual disability, seizures, and movement disorders. Unlike the severe neonatal form, individuals with atypical NKH may present symptoms in infancy, childhood, or even adulthood. Diagnosis typically involves the measurement of elevated glycine concentrations in plasma and cerebrospinal fluid, followed by genetic testing to identify causative mutations in GCS-related genes. Early diagnosis is crucial for implementing therapeutic strategies, which may include dietary modifications (glycine restriction) and pharmacotherapy. Treatments often involve sodium benzoate, which helps excrete excess glycine, andNMDAreceptor antagonists like dextromethorphan, which aim to counteract the excitatory effects of glycine in the brain. Understanding metabolic disorders like atypical glycine encephalopathy benefits from research into the broader human metabolome and specific metabolite quantitative trait loci^[1]. ^[2]

Social Importance

The social significance of atypical glycine encephalopathy lies in its profound impact on affected individuals and their families. The rarity and variable presentation of the condition often lead to diagnostic delays, causing prolonged uncertainty and potentially missing critical windows for early intervention. Accurate diagnosis is essential for appropriate medical management, genetic counseling, and informed family planning. Continued research into the genetic and metabolic underpinnings of this disorder aims to improve diagnostic tools, develop more effective treatments, and enhance the overall quality of life for those affected, fostering better integration and support within society.

Limitations

Methodological and Statistical Considerations

The research faced limitations stemming from varying sample sizes across tested variants, which particularly impacted the detection of rare variants or those covered by specific imputation panels These genetic differences highlight how specific single nucleotide polymorphisms (SNPs) can influence broader metabolic profiles and contribute to individual health variations.^[3]

Specifically, the rs738409 variant, which results in an isoleucine-to-methionine substitution at amino acid position 148 (I148M), is widely recognized for its strong association with increased liver fat content and a higher risk of non-alcoholic fatty liver disease (NAFLD) and its progression to more severe forms like non-alcoholic steatohepatitis (NASH). WhilePNPLA3variants are not directly involved in glycine metabolism, the intricate balance of metabolic pathways means that significant disruptions in lipid processing, influenced by variants likers3747207 and rs738409 , can have systemic effects that impact overall cellular function. These broad metabolic influences can indirectly affect the brain and may potentially modulate the presentation or severity of complex neurological conditions such as atypical glycine encephalopathy, a disorder primarily affecting glycine metabolism.^[4]

Another gene of interest is SDK1, or Sidekick Cell Adhesion Molecule 1, which is vital for proper neuronal development and function. SDK1 encodes a cell adhesion molecule that belongs to the immunoglobulin superfamily, a group of proteins critical for cell-to-cell communication and structural organization within tissues, particularly in the brain. This protein is involved in processes such as synapse formation and the precise layering of cells in the retina, contributing to the establishment of functional neural circuits. ^[5] Genetic variants, such as rs12701046 , can influence the expression or activity of the SDK1 protein, potentially leading to subtle alterations in neuronal connectivity and brain architecture. ^[6]

While SDK1 and its variant rs12701046 are not directly linked to the biochemical pathways of glycine metabolism, their role in maintaining healthy neuronal structure and connectivity is paramount for overall neurological well-being. Atypical glycine encephalopathy is characterized by severe neurological dysfunction stemming from impaired glycine metabolism, and any factor that compromises neuronal integrity or development could potentially exacerbate or contribute to the clinical features of such a condition. Therefore, variations in genes likeSDK1 that impact fundamental brain development and function, even if indirectly, underscore the complex genetic landscape underlying neurological disorders and the potential for overlapping symptomatic traits. ^[3]

Causes of Atypical Glycine Encephalopathy

Atypical glycine encephalopathy is a complex neurological disorder influenced by a combination of genetic predispositions, environmental factors, and the intricate interplay between them. The etiology involves disruptions in metabolic pathways, often stemming from variations in an individual’s genetic code that are further modulated by external influences.

Genetic Predisposition and Molecular Mechanisms

Genetic factors play a fundamental role in the development of atypical glycine encephalopathy by influencing metabolic processes at a foundational level. Whole-genome association studies (GWAS) and quantitative trait loci (QTLs) have revealed that variations in the genome can significantly impact an individual’s metabolome, linking specific inherited variants to measurable differences in metabolite levels.^[1] This indicates a polygenic risk component, where multiple genetic loci collectively contribute to the susceptibility and expression of conditions affecting metabolism. Furthermore, the genetic landscape extends beyond metabolites to influence protein expression, with genetic variations impacting protein levels through a process known as proteo-genomic convergence. ^[7]This mechanism suggests that the molecular basis of atypical glycine encephalopathy can involve genetic alterations that lead to dysfunctional protein levels, thereby disrupting critical biological pathways.

Environmental Modulators and Gene-Environment Interactions

Environmental factors, particularly dietary intake, are crucial in modulating the genetic predispositions associated with atypical glycine encephalopathy. Research has demonstrated that dietary factors can interact with metabolite quantitative trait loci (QTLs) in children, influencing the levels of various urinary metabolites.^[1]This highlights that an individual’s genetic makeup does not operate in isolation but is dynamically influenced by external elements such as their diet. Such gene-environment interactions mean that specific dietary choices can either exacerbate or mitigate the impact of inherited genetic variants on metabolic profiles, consequently affecting the phenotypic manifestation of the encephalopathy.

Systemic and Metabolic Contributions

The development of atypical glycine encephalopathy can also be understood within a broader systemic context, where genetic and molecular factors converge to influence overall physiological function. Genetic variations lead to altered protein levels, creating a proteo-genomic convergence that forms the underlying molecular basis for a range of human diseases.^[7]This suggests that the impact of genetics extends through complex networks of protein interactions, affecting multiple biological systems. Additionally, whole-genome association studies have identified metabolites linked to cardiometabolic disease, indicating that metabolic dysregulation—influenced by genetic factors—can contribute to wider systemic health issues.^[2]These broader metabolic and systemic disturbances, while not always directly causal for atypical glycine encephalopathy, can represent contributing factors or co-occurring conditions that influence its presentation or severity.

Biological Background

Glycine Metabolism and its Central Role

Glycine is a fundamental nonessential amino acid with diverse physiological functions, acting as a building block for proteins and playing crucial roles in various metabolic pathways.^[8] Its metabolism is intricately linked to other vital biomolecules and cellular processes. ^[9]A key metabolic pathway involving glycine is the glycine cleavage system (GCS), a multi-enzyme complex that facilitates the interconversion of glycine to ammonia and carbon dioxide^[3]. ^[10]This system is essential for maintaining glycine homeostasis and also contributes to the one-carbon metabolism, which is critical for nucleotide synthesis and methylation reactions.

Beyond its metabolic roles, glycine also functions as an inhibitory neurotransmitter in the central nervous system, particularly in the spinal cord and brainstem.^[11]Disruptions in glycine metabolism can therefore impact neurological function. Furthermore, glycine metabolism is closely intertwined with serine metabolism, with genes likeALDH1L1 and GLDCinfluencing the serine to glycine ratio in the body.^[12]This metabolic axis is vital for cellular proliferation and survival, and its dysregulation has implications for various health conditions, including cancer.^[13]

Genetic Regulation of Glycine Homeostasis

The levels of circulating glycine and related metabolites are under significant genetic control, as revealed by genome-wide association studies (GWAS)^[4]. ^[3]These studies have identified numerous genetic loci and specific genes that influence amino acid concentrations^{[14], [15]}. ^[16] For instance, variants in ALDH1L1 and GLDCare known to affect the balance between serine and glycine, highlighting their role in this critical metabolic interconversion.^[12]

Other genes, such as PYCR1, have been found where missense variants lead to decreased glycine levels, potentially indicating reduced oxidative potential within cells.^[15] Similarly, genes involved in related metabolic pathways, like DMGDH and BHMTin dimethyl-glycine and betaine metabolism, orBCAT2in branched-chain amino acid breakdown, can indirectly influence glycine levels and overall metabolic health^[17]. ^[15] The genetic regulation extends to transporters like SLC16A9, which impacts the transport of various molecules, including organic anions and bile salts, thereby affecting broader metabolic profiles. ^[17] Such genetic insights provide important opportunities for identifying potential pharmacogenomic targets and developing new therapeutic strategies. ^[3]

Pathophysiology of Hyperglycinemia and Associated Metabolic Disorders

Atypical glycine encephalopathy is characterized by disruptions in glycine metabolism, often leading to elevated levels of glycine, a condition known as hyperglycinemia.^[10]This can arise from defects in the glycine cleavage system, which is responsible for breaking down glycine.^[10]Such metabolic imbalances can have profound neurological consequences, as glycine is an important neurotransmitter.^[11]

Hyperglycinemia can also be associated with other inborn errors of metabolism, such as congenital hyperammonemia, where there is a decrease in carbamyl phosphate synthetase levels and defects in the mitochondrial portion of the urea cycle^[18]. ^[19]These interconnected metabolic disruptions can lead to a complex array of symptoms. For example, disorders affecting branched-chain amino acid metabolism, such as those caused by variants inBCAT2, can result in high levels of amino acids like valine, leucine, and isoleucine, leading to neurological symptoms similar to Maple Syrup Urine Disease.^[15]

Systemic Impacts and Disease Associations

The widespread involvement of glycine in metabolism means that its dysregulation can have systemic consequences beyond the central nervous system. Genetically determined variations in serum glycine levels have been linked to an increased risk of cardio-metabolic diseases^{[4], [20]}. ^[21]Studies indicate that glycine plays a role in insulin sensitivity and glutathione biosynthesis, and can protect against oxidative stress.^[22]Conversely, impaired glycine metabolism has been observed in conditions like type 2 diabetes.^[23]

At the organ level, glycine metabolism is relevant to liver function, with studies exploring acyl-CoA:glycineactivities in liver fractions and serine deficiency in non-alcoholic fatty liver disease^[24]. ^[25]Furthermore, glycine supplementation has shown potential in mitigating lead-induced renal injury.^[26]The intricate network of metabolic pathways, including those involving purines, pyruvate, and various signaling cascades, underscores how disruptions in a seemingly simple amino acid like glycine can cascade into broad physiological dysfunctions affecting multiple tissues and organ systems, including the nervous, digestive, endocrine, and excretory systems.^[27]

Pathways and Mechanisms

Central Glycine Metabolic Pathways and Regulation

Atypical glycine encephalopathy primarily involves dysregulation of central glycine metabolic pathways, particularly those governing its catabolism and interconversion with serine. The glycine cleavage system (GCS), composed of multiple enzymatic components, represents the principal catabolic pathway for glycine, facilitating its interconversion to ammonia.^[10]This system’s efficiency is crucial for maintaining glycine homeostasis, as evidenced by its physiological significance in glycine turnover and decarboxylation rates.^[28]Furthermore, the metabolic interplay between serine and glycine is critical, with genetic variants in enzymes such asGLDC(glycine decarboxylase, a component of GCS) andALDH1L1influencing the cellular serine to glycine ratio, thereby impacting both biosynthesis and catabolic flux control.^[12]

The regulation of these interconnected pathways involves intricate control mechanisms at the genetic level, influencing the expression and activity of key enzymes. For instance, phosphoserine phosphatase deficiency impacts serine synthesis, consequently affecting glycine availability due to their interdependency.^[29]Beyond direct catabolism, glycine also participates in other metabolic processes like conjugation reactions, where enzymes like glycine N-acyltransferase (GLYAT) are involved, reflecting a broader regulatory network that modulates glycine’s metabolic fate and overall flux.^[30]

Glycine’s Neurotransmitter Function and Systemic Interconnections

Glycine is not only a fundamental metabolic building block but also an important inhibitory neurotransmitter within the central nervous system, influencing neuronal excitability and synaptic function.^[11] Its role extends to regulating nervous system pathways, including GABAergic and glutamatergic synapses, highlighting its direct involvement in neurological processes relevant to encephalopathy. ^[27]Beyond its direct neural actions, glycine metabolism is deeply integrated into systemic metabolic networks, exhibiting significant crosstalk with other essential pathways such as the urea cycle, where congenital hyperammonemia has been associated with hyperglycinemia and decreased carbamyl phosphate synthetase levels.^[18]

This systems-level integration is further exemplified by glycine’s impact on energy metabolism and glucose homeostasis, as alterations in glycine metabolism are observed in conditions like obesity and metabolic diseases.^[31]Glycine has been shown to increase insulin sensitivity and glutathione biosynthesis, protecting against oxidative stress, while impaired glycine levels are linked to type 2 diabetes and glucose regulation.^[32]These interactions underscore a hierarchical regulation where glycine metabolism influences and is influenced by broader physiological states, contributing to emergent properties that affect overall health and disease susceptibility.

Genetic and Epigenetic Modulators of Glycine Homeostasis

Genetic variations play a crucial role in determining individual glycine levels and influencing metabolic individuality. Genome-wide association studies (GWAS) have identified multiple genetic loci associated with circulating glycine concentrations, with genetic scores comprising several variants explaining a substantial portion of the variance in glycine levels.^[20] Specific genes such as ALDH1L1 and GLDCare known to influence the serine to glycine ratio, directly affecting the balance of these amino acids.^[12] Other genes, including DMGDH and BHMT, are involved in dimethyl-glycine and betaine metabolism, pathways that can offer compensatory mechanisms for glycine homeostasis.^[17]

Furthermore, variants in genes like PYCR1have been linked to decreased glycine levels, suggesting broader impacts on amino acid metabolism and oxidative potential.^[33] The enzyme OPLAH(5-oxoprolinase), which converts 5-oxoproline to glutamic acid, also represents a point of genetic influence on amino acid balance.^[34]These genetic determinants regulate not only the expression of metabolic enzymes but also their functional properties, potentially through protein modifications and allosteric control, thereby dictating the efficiency of glycine synthesis, breakdown, and interconversion, and ultimately contributing to the phenotypic spectrum of atypical glycine encephalopathy.

Pathophysiological Consequences and Therapeutic Avenues

The core disease-relevant mechanism in atypical glycine encephalopathy is the dysregulation of glycine metabolism, leading to elevated glycine levels that disrupt normal neurological function. This pathway dysregulation, often rooted in genetic variants affecting enzymes like those in the glycine cleavage system, directly contributes to the encephalopathic phenotype.^[10] Understanding these precise molecular interactions provides critical insights into the pathogenesis of the condition.

In response to primary pathway defects, compensatory mechanisms may emerge, such as the potential role of dietary betaine in modulating glycine bioavailability and metabolism.^[12]Identifying these mechanisms is crucial for developing targeted interventions. Therapeutic strategies could involve pharmacologic modulation of serine metabolism or direct supplementation with serine or glycine, aiming to restore metabolic balance and alleviate disease symptoms.^[35]Such interventions represent promising therapeutic targets, highlighting the importance of a mechanistic understanding of glycine pathways in managing this complex neurological disorder.

Pharmacogenetics of Atypical Glycine Encephalopathy

Atypical glycine encephalopathy, characterized by disturbances in glycine metabolism, presents a complex landscape for therapeutic intervention. Pharmacogenetics offers a crucial lens through which to understand inter-individual variability in drug response, by examining how genetic differences influence drug metabolism, transport, and target interaction. Research into metabolic individuality and genetic influences on human blood metabolites has begun to identify specific variants with potential pharmacogenomic relevance, paving the way for more personalized treatment strategies.^[3]

Genetic Influences on Drug Metabolism and Transport

Genetic variations play a significant role in determining how individuals metabolize and transport drugs, which is crucial for managing conditions like atypical glycine encephalopathy. Studies have identified numerous genes, including 11 drug-metabolizing enzymes and 3 drug transporters, that are targets for FDA- and/or EMA-approved drugs.^[3] For instance, variants in genes like SLC16A9, a transporter involved in drug, bile salt, and organic anion transport, can influence drug pharmacokinetics. The rs1171614 variant, for example, has been shown to affect SLC16A9 expression, potentially altering the absorption, distribution, and excretion of various compounds. ^[17] Such genetic differences can lead to variable drug exposure and necessitate personalized dosing strategies.

Variants Affecting Glycine Pathway Drug Targets

Atypical glycine encephalopathy involves dysregulation of glycine metabolism, and genetic variants in key enzymes within this pathway can significantly alter an individual’s response to therapeutic interventions. Genes such asGLDC, a component of the glycine cleavage complex, andALDH1L1are known to influence the critical serine to glycine ratio^[12]. ^[35]Polymorphisms in these genes can lead to altered baseline metabolite levels, potentially affecting the efficacy of drugs designed to modulate glycine concentrations or related pathways. Additionally, variants in enzymes likeDMGDH and BHMT, which are involved in dimethyl-glycine and betaine metabolism, orCPS1(carbamoyl-phosphate synthase 1), can introduce metabolic individuality that impacts the effectiveness and safety of pharmacologic agents.^[17] Understanding these target-related variants is essential for predicting therapeutic response and tailoring drug selection.

Pharmacokinetic and Pharmacodynamic Implications

The interplay between genetic variants and drug response encompasses both pharmacokinetic (PK) and pharmacodynamic (PD) aspects, which are critical for optimizing treatment outcomes in atypical glycine encephalopathy. On the PK side, genetic variations in drug transporters, such as thers1171614 variant influencing SLC16A9 expression, can alter drug absorption, distribution, and elimination, leading to inter-individual variability in systemic drug exposure. ^[17] From a PD perspective, polymorphisms in metabolic genes like GLDC, DMGDH, or CPS1 can modify the underlying metabolic environment, thereby affecting how a drug interacts with its target or signaling pathways ^[17]. ^[12] These genetic factors collectively determine drug efficacy and the propensity for adverse reactions, highlighting the need for a comprehensive pharmacogenetic assessment.

Personalized Therapeutic Approaches

Integrating pharmacogenetic insights into the clinical management of atypical glycine encephalopathy offers a pathway toward personalized medicine, optimizing therapeutic strategies based on an individual’s genetic makeup. The identification of genetic variants in drug-metabolizing enzymes, transporters, and drug targets provides actionable information that can guide dosing adjustments and drug selection.^[3]For instance, knowledge of variants influencing drug transport or glycine pathway enzymes can inform clinicians to select alternative drugs or modify dosages to achieve desired therapeutic effects while minimizing adverse events. This precision medicine approach, supported by genetic insights into metabolic individuality, aims to improve patient outcomes by moving beyond a one-size-fits-all treatment paradigm.^[34]

Key Variants

RS ID	Gene	Related Traits
rs3747207 rs738409	PNPLA3	platelet count serum alanine aminotransferase amount aspartate aminotransferase measurement triglyceride measurement non-alcoholic fatty liver disease
rs12701046	SDK1	Encephalopathy

Frequently Asked Questions About Atypical Glycine Encephalopathy

These questions address the most important and specific aspects of atypical glycine encephalopathy based on current genetic research.

---

1. My child has some delays; could it be this rare problem?

It’s possible, as atypical glycine encephalopathy can cause mild developmental delays and learning difficulties, sometimes appearing in infancy or childhood. Unlike the severe form, symptoms can be subtle and vary widely, making diagnosis challenging. If you have concerns, your doctor can explore specialized tests to measure glycine levels.

2. I’ve always struggled with learning. Is it something genetic?

Yes, persistent learning difficulties can be a symptom of atypical glycine encephalopathy, which is a genetic condition. This disorder affects how your body processes glycine, an amino acid, leading to its accumulation in the brain and impacting normal neurotransmission. Identifying the underlying genetic cause can lead to targeted management.

3. Why did it take doctors so long to diagnose my issues?

This condition is rare, and its symptoms can be very diverse, appearing from infancy to adulthood. This wide spectrum of presentation often leads to diagnostic delays, as doctors may not immediately suspect it. Increased awareness and specialized metabolic and genetic testing are crucial for an earlier diagnosis.

4. If I have this, will my future children definitely inherit it?

Not necessarily “definitely,” but there is a genetic risk. Atypical glycine encephalopathy is inherited, and if you have it, genetic counseling can explain the specific inheritance pattern for your family. This helps you understand the chances of passing on mutations in genes likeGLDC or AMT to your children.

5. My sibling is healthy, but I have these symptoms. Why the difference?

The condition is known for its wide spectrum of severity, even within the same family. This “atypical” nature means that some individuals have enough residual activity of the glycine cleavage system to show milder or later-onset symptoms, while others might be unaffected carriers or have different genetic variations.

6. Will changing my diet really help my brain function better?

Yes, dietary modifications, specifically restricting glycine intake, can be a crucial part of managing atypical glycine encephalopathy. This helps reduce the overall glycine load in your body. Combined with medications like sodium benzoate, it aims to lower glycine levels in the brain and improve neurological function.

7. Can medication actually fix problems with my brain’s chemistry?

Medications can significantly help manage the chemical imbalances in your brain caused by this condition. For example, sodium benzoate helps your body excrete excess glycine, while drugs like dextromethorphan can counteract the disruptive effects of high glycine onNMDA receptors, helping to alleviate neurological symptoms.

8. I’m an adult, could my recent symptoms be from this condition?

Yes, atypical glycine encephalopathy can present in adulthood, not just in childhood. While it’s rare, symptoms like new-onset learning difficulties, behavioral changes, or movement disorders could potentially be related. It’s important to discuss any new or worsening neurological symptoms with your doctor for proper evaluation.

9. What kind of specialized testing would confirm this for me?

Diagnosis typically involves measuring elevated glycine concentrations in both your plasma (blood) and cerebrospinal fluid (CSF), which is usually taken via a spinal tap. Following this, genetic testing is used to identify specific mutations in genes related to the glycine cleavage system, such asGLDC or AMT.

10. Does my family need to worry about this if I have it?

It’s important for your family to be aware, especially for genetic counseling and family planning. Since it’s a genetic condition, other family members might be carriers or at risk. Understanding the genetic basis allows for informed decisions and early intervention if other family members are affected.

---

This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.

Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.

References

[1] Calvo-Serra, B. et al. “Urinary metabolite quantitative trait loci in children and their interaction with dietary factors.”Hum Mol Genet, vol. 29, no. 23, 2020.

[2] Tahir, U. A. et al. “Whole Genome Association Study of the Plasma Metabolome Identifies Metabolites Linked to Cardiometabolic Disease in Black Individuals.”Nat Commun, vol. 13, no. 4923, 2022.

[3] Shin SY, et al. “An atlas of genetic influences on human blood metabolites.” Nat Genet. 2014.

[4] Jia Q, et al. “Genetic Determinants of Circulating Glycine Levels and Risk of Coronary Artery Disease.” J Am Heart Assoc. 2019.

[5] Imaizumi A, et al. “Genetic basis for plasma amino acid concentrations based on absolute quantification: a genome-wide association study in the Japanese population.” Eur J Hum Genet. 2019.

[6] Draisma HHM, et al. “Genome-wide association study identifies novel genetic variants contributing to variation in blood metabolite levels.” Nat Commun. 2015.

[7] Pietzner, M. et al. “Mapping the proteo-genomic convergence of human diseases.” Science, 2021.

[8] Razak, M. A., et al. “Multifarious beneficial effect of nonessential amino acid, glycine: a review.”Oxidative Medicine and Cellular Longevity 2017 (2017): 1716701.

[9] Wang, W., et al. “Glycine metabolism in animals and humans: implications for nutrition and health.”Amino Acids 45.3 (2013): 463-477.

[10] Kikuchi, G., et al. “Glycine cleavage system: reaction mechanism, physiological significance, and hyperglycinemia.”Proceedings of the Japan Academy, Series B, Physical and Biological Sciences 84.8 (2008): 246-263.

[11] Bowery, N. G., and T. G. Smart. “GABA and glycine as neurotransmitters: a brief history.”Br J Pharmacol, vol. 147, no. S1, 2006, pp. S109–19.

[12] Krupenko, S. A., et al. “Genetic variants in ALDH1L1 and GLDCinfluence serine to glycine ratio in Hispanic children.”The American Journal of Clinical Nutrition 115.6 (2022): 1599-1608.

[13] Amelio, I., et al. “Serine and glycine metabolism in cancer.”Trends Biochem. Sci., vol. 39, 2014, pp. 191–198.

[14] Kettunen, J., et al. “Genome-wide association study identifies multiple loci influencing human serum metabolite levels.” Nature Genetics 44.3 (2012): 269-276.

[15] Teslovich, T. M., et al. “Identification of seven novel loci associated with amino acid levels using single-variant and gene-based tests in 8545 Finnish men from the METSIM study.”Human Molecular Genetics 28.5 (2019): 855-865.

[16] Hysi, P. G., et al. “Metabolome Genome-Wide Association Study Identifies 74 Novel Genomic Regions Influencing Plasma Metabolites Levels.” Metabolites 12.1 (2022): 89.

[17] Demirkan, A., et al. “Insight in genome-wide association of metabolite quantitative traits by exome sequence analyses.” PLoS Genet, vol. 11, no. 1, 2015, e1004872.

[18] Freeman, J. M., et al. “Congenital hyperammonemia. Association with hyperglycinemia and decreased levels of carbamyl phosphate synthetase.”Arch Neurol, vol. 23, 1970, pp. 430–437.

[19] Colombo, J. P., et al. “Inborn defects of the mitochondrial portion of the urea cycle.”Ann N Y Acad Sci, vol. 488, 1986, pp. 109–117.

[20] Wittemans, L. B. L., et al. “Assessing the causal association of glycine with risk of cardio-metabolic diseases.”Nat Commun, vol. 10, no. 1, 2019, p. 1013.

[21] Chang, X., et al. “The association of genetically determined serum glycine with cardiovascular risk in East Asians.”Nutrition, Metabolism and Cardiovascular Diseases 31.8 (2021): 2291-2298.

[22] El-Hafidi, M., et al. “Glycine increases insulin sensitivity and glutathione biosynthesis and protects against oxidative stress in a model of sucrose-induced insulin resistance.”Oxidative Medicine and Cellular Longevity 2018 (2018).

[23] Yan-Do, R., and P. E. MacDonald. “Impaired ‘glycine’-mia in type 2 diabetes and potential mechanisms contributing to glucose homeostasis.”Endocrinology 158.4 (2017): 1064-1073.

[24] Webster, L. T., et al. “Identification of separate acyl-CoA: glycine and activities in fractions from liver of rhesus monkey and man.”Journal of Biological Chemistry 251.11 (1976): 3352-3358.

[25] Mardinoglu, A., et al. “Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease.”Nature Communications 5.1 (2014): 3083.

[26] Shafiekhani, M., et al. “Glycine supplementation mitigates lead-induced renal injury in mice.”Journal of Experimental Pharmacology 11 (2019): 15-22.

[27] Jung, T., et al. “Integrative Pathway Analysis of SNP and Metabolite Data Using a Hierarchical Structural Component Model.” Front Genet, vol. 13, 2022, p. 814412.

[28] Lamers, Y., et al. “Glycine turnover and decarboxylation rate quantified in healthy men and women using primed, constant infusions of [1,2-(13)C2]glycine and [(2)H3]leucine.”The Journal of Nutrition 137.12 (2007): 2647-2652.

[29] JIMD Rep., vol. 30, 2016, pp. 103–108. (Novel report of phosphoserine phosphatase deficiency in an adult with myeloneuropathy and limb contractures.)

[30] Badenhorst, C. P., et al. “Glycine conjugation: importance in metabolism, the role of glycine N-acyltransferase, and factors that influence interindividual variation.”Expert Opin Drug Metab Toxicol, vol. 9, no. 9, 2013, pp. 1139–53.

[31] Alves, A., et al. “Glycine metabolism and its alterations in obesity and metabolic diseases.”Nutrients 11.6 (2019): 1356.

[32] El-Hafidi, M., et al. “Glycine increases insulin sensitivity and glutathione biosynthesis and protects against oxidative stress in a model of sucrose-induced insulin resistance.”Oxid. Med. Cell. Longev., 2018, 2101562.

[33] Teslovich, T. M., et al. “Identification of seven novel loci associated with amino acid levels using single-variant and gene-based tests in 8545 Finnish men from the METSIM study.”Hum Mol Genet, vol. 27, no. 6, 2018, pp. 1121–1132.

[34] Surendran, P., et al. “Rare and common genetic determinants of metabolic individuality and their effects on human health.” Nat Med, vol. 28, no. 11, 2022, pp. 2420–2433.

[35] Lotta, L. A., et al. “A cross-platform approach identifies genetic regulators of human metabolism and health.” Nat Genet, vol. 53, no. 2, 2021, pp. 176–186.